LENZ Therapeutics (NASDAQ:LENZ) Given Outperform Rating at Leerink Partnrs

Leerink Partnrs restated their outperform rating on shares of LENZ Therapeutics (NASDAQ:LENZ) in a research note released on Monday, Zacks.com reports. Leerink Partnrs also issued estimates for LENZ Therapeutics’ Q1 2024 earnings at ($0.51) EPS, Q2 2024 earnings at ($0.47) EPS, Q3 2024 earnings at ($0.40) EPS, Q4 2024 earnings at ($0.42) EPS, FY2024 earnings at ($1.80) EPS, FY2025 earnings at ($2.20) EPS, FY2026 earnings at ($1.30) EPS, FY2027 earnings at $0.85 EPS and FY2028 earnings at $2.70 EPS.

A number of other equities research analysts have also issued reports on LENZ. SVB Leerink began coverage on shares of LENZ Therapeutics in a research note on Monday. They issued an outperform rating and a $32.00 target price on the stock. William Blair assumed coverage on shares of LENZ Therapeutics in a research note on Monday. They set an outperform rating on the stock. Citigroup assumed coverage on shares of LENZ Therapeutics in a research note on Wednesday, April 10th. They set a buy rating and a $34.00 price objective on the stock. Finally, Piper Sandler assumed coverage on shares of LENZ Therapeutics in a research note on Wednesday, March 27th. They set an overweight rating and a $28.00 price objective on the stock. Five analysts have rated the stock with a buy rating, According to MarketBeat, LENZ Therapeutics has an average rating of Buy and an average price target of $31.33.

LENZ Therapeutics Price Performance

Shares of LENZ Therapeutics stock opened at $17.49 on Monday. LENZ Therapeutics has a twelve month low of $14.07 and a twelve month high of $29.82. The firm has a market cap of $145.52 million, a P/E ratio of -1.12 and a beta of 0.20.

Insiders Place Their Bets

In other LENZ Therapeutics news, Director Ra Capital Management, L.P. purchased 998,009 shares of the business’s stock in a transaction dated Thursday, March 21st. The shares were acquired at an average price of $15.03 per share, for a total transaction of $15,000,075.27. Following the acquisition, the director now owns 3,319,339 shares of the company’s stock, valued at $49,889,665.17. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 38.40% of the company’s stock.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.